biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CERO. Primary therapeutic focus areas include Non small cell lung cancer, oligometastatic hormone sens
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
IFCT-1805
Phase 3 · small molecule · Non Small Cell Lung Cancer
IFCT-1805 for Non Small Cell Lung Cancer is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Internal code IFCT-1805
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CERO THERAPEUTICS HOLDINGS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Non Small Cell Lung Cancer
- Status
- active
- Trials
- 1